{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:19:48Z","timestamp":1785302388779,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s42000-020-00251-5","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T20:02:31Z","timestamp":1604347351000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Nikolaos","family":"Pyrgidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Vakalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-571X","authenticated-orcid":false,"given":"Petros","family":"Sountoulides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"issue":"1","key":"251_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"251_CR2","volume-title":"Facts & figures 2020","author":"American Cancer Society","year":"2020","unstructured":"American Cancer Society (2020) Facts & figures 2020. American Cancer Society, Atlanta"},{"key":"251_CR3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol. Elsevier 65:1046\u20131055","journal-title":"Eur Urol"},{"issue":"4","key":"251_CR4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/pcan.2014.35","volume":"17","author":"A Patrikidou","year":"2014","unstructured":"Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E et al (2014) Who dies from prostate cancer? Prostate Cancer Prostatic Dis 17(4):348\u2013352","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"251_CR5","unstructured":"Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S et al (2020) EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2020. In: European Association of Urology guidelines 2020 edition. European Association of Urology Guidelines Office, Arnhem"},{"issue":"3","key":"251_CR6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J et al (2018) Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199(3):683\u2013690","journal-title":"J Urol"},{"issue":"3","key":"251_CR7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","volume":"77","author":"DE Neal","year":"2020","unstructured":"Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ et al (2020) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol 77(3):320\u2013330","journal-title":"Eur Urol"},{"issue":"1","key":"251_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40259-015-0116-7","volume":"29","author":"BA Baldo","year":"2015","unstructured":"Baldo BA (2015) Enzymes approved for human therapy: indications, mechanisms and adverse effects. BioDrugs. 29(1):31\u201355","journal-title":"BioDrugs."},{"key":"251_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A et al (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. Nat Publ Group 22:24\u201338","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"251_CR10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","volume":"103","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 103(8):1615\u20131624","journal-title":"Cancer."},{"issue":"15","key":"251_CR11","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","volume":"115","author":"H Akaza","year":"2009","unstructured":"Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 115(15):3437\u20133445","journal-title":"Cancer."},{"issue":"97","key":"251_CR12","doi-asserted-by":"crossref","first-page":"36966","DOI":"10.18632\/oncotarget.26426","volume":"9","author":"S Tamada","year":"2018","unstructured":"Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S et al (2018) Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 9(97):36966\u201336974","journal-title":"Oncotarget."},{"issue":"2","key":"251_CR13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158","journal-title":"Lancet Oncol"},{"key":"251_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","volume":"19","author":"ES Antonarakis","year":"2016","unstructured":"Antonarakis ES, Armstrong AJ, Dehm SM, Luo J (2016) Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. Nat Publ Group 19:231\u2013241","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"251_CR15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","volume":"67","author":"T Karantanos","year":"2015","unstructured":"Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB (2015) Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470\u2013479","journal-title":"Eur Urol"},{"key":"251_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/pcan.2011.24","volume":"14","author":"ES Antonarakis","year":"2011","unstructured":"Antonarakis ES, Armstrong AJ (2011) Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. Nat Publ Group 14:206\u2013218","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"251_CR17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fneur.2019.00801","volume":"10","author":"MA Rice","year":"2019","unstructured":"Rice MA, Malhotra SV, Stoyanova T (2019) Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Neurol. Frontiers Media S.A. 10:801","journal-title":"Front Neurol"},{"issue":"10","key":"251_CR18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992","journal-title":"Lancet Oncol"},{"issue":"2","key":"251_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160","journal-title":"Lancet Oncol"},{"issue":"2","key":"251_CR20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"21","key":"251_CR21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"2","key":"251_CR22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis CJ, De Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"13","key":"251_CR23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"5","key":"251_CR24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"26","key":"251_CR25","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465\u20132474","journal-title":"N Engl J Med"},{"issue":"15","key":"251_CR26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"N Engl J Med"},{"issue":"13","key":"251_CR27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235\u20131246","journal-title":"N Engl J Med"},{"issue":"4","key":"251_CR28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"4","key":"251_CR29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, De Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"32","key":"251_CR30","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"2","key":"251_CR31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121\u2013131","journal-title":"N Engl J Med"},{"issue":"1","key":"251_CR32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13\u201324","journal-title":"N Engl J Med"},{"key":"251_CR33","first-page":"240108","volume":"2013","author":"P Sountoulides","year":"2013","unstructured":"Sountoulides P, Rountos T (2013) Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol 2013:240108","journal-title":"ISRN Urol"},{"key":"251_CR34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SMH, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. Elsevier 67:825\u2013836","journal-title":"Eur Urol"},{"key":"251_CR35","doi-asserted-by":"crossref","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197\u20132206","DOI":"10.1056\/NEJMoa2003892"},{"issue":"12","key":"251_CR36","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M et al (2004) Hormonal impact of the 17\u03b1-hydroxylase\/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317\u20132325","journal-title":"Br J Cancer"},{"issue":"28","key":"251_CR37","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563\u20134571","journal-title":"J Clin Oncol"},{"issue":"2","key":"251_CR38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E et al (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97(2):507\u2013516","journal-title":"J Clin Endocrinol Metab"},{"key":"251_CR39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1756287218786160","volume":"10","author":"M Marchioni","year":"2018","unstructured":"Marchioni M, Sountoulides P, Bada M, Rapisarda S, De Nunzio C, Tamburro FR et al (2018) Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of \u2018real-life\u2019 studies. Ther Adv Urol. SAGE Publications Inc. 10:305\u2013315","journal-title":"Ther Adv Urol"},{"issue":"5928","key":"251_CR40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (80-) 324(5928):787\u2013790","journal-title":"Science (80-)"},{"key":"251_CR41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMe1409306","volume":"371","author":"PS Nelson","year":"2014","unstructured":"Nelson PS (2014) Targeting the androgen receptor in prostate cancer - a resilient foe. N Engl J Med. Massachussetts Medical Society 371:1067\u20131069","journal-title":"N Engl J Med"},{"key":"251_CR42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2018.04.083","volume":"200","author":"ED Crawford","year":"2018","unstructured":"Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N et al (2018) Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol. Elsevier Inc. 200:956\u2013966","journal-title":"J Urol"},{"issue":"6","key":"251_CR43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A et al (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72(6):1494\u20131503","journal-title":"Cancer Res"},{"key":"251_CR44","doi-asserted-by":"crossref","unstructured":"Baumgart SJ, Nevedomskaya E, Lesche R, Newman R, Mumberg D, Haendler B (2020) Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation. Mol Oncol","DOI":"10.1002\/1878-0261.12693"},{"key":"251_CR45","doi-asserted-by":"crossref","unstructured":"Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G et al (2015) Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5","DOI":"10.1038\/srep12007"},{"key":"251_CR46","doi-asserted-by":"crossref","unstructured":"Taavitsainen P, Gieschen H, Korjamo T, K\u00e4hk\u00f6nen M, Malmstr\u00f6m C, Prien O et al (2020) Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. Xenobiotica","DOI":"10.1080\/00498254.2020.1723038"},{"issue":"5","key":"251_CR47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"key":"251_CR48","unstructured":"INN-abiraterone; Zytiga; Annex I: summary of product characteristis. [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zytiga-epar-product-information_en.pdf"},{"issue":"3","key":"251_CR49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2016.02.035","volume":"70","author":"K Fizazi","year":"2016","unstructured":"Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE et al (2016) Low incidence of corticosteroid-associated adverse events on long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer. Eur Urol 70(3):438\u2013444","journal-title":"Eur Urol"},{"issue":"8","key":"251_CR50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","volume":"5","author":"G Attard","year":"2019","unstructured":"Attard G, Merseburger AS, Arlt W, Sternberg CN, Feyerabend S, Berruti A et al (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol 5(8):1159\u20131167","journal-title":"JAMA Oncol"},{"key":"251_CR51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028017728297","volume":"52","author":"MD Wallace","year":"2018","unstructured":"Wallace MD, Metzger NL (2018) Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother. SAGE Publications Inc. 52:86\u201390","journal-title":"Ann Pharmacother"},{"issue":"1","key":"251_CR52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","volume":"46","author":"RM Joseph","year":"2016","unstructured":"Joseph RM, Hunter AL, Ray DW, Dixon WG (2016) Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 46(1):133\u2013141","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"251_CR53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","volume":"27","author":"JN Graff","year":"2016","unstructured":"Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW et al (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27(2):286\u2013294","journal-title":"Ann Oncol"},{"issue":"5","key":"251_CR54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaoncol.2017.3361","volume":"4","author":"S Slovin","year":"2018","unstructured":"Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F et al (2018) Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol 4(5):702\u2013706","journal-title":"JAMA Oncol"},{"issue":"11","key":"251_CR55","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JOP.2017.022004","volume":"13","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG (2017) Management of anticoagulation in patients with prostate cancer receiving enzalutamide. J Oncol Pract 13(11):720\u2013727","journal-title":"J Oncol Pract"},{"key":"251_CR56","unstructured":"INN-enzalutamide; Xtandi; Annex I: summary of product characteristis. [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf"},{"key":"251_CR57","unstructured":"INN-apalutamide; Erleada; Annex I: summary of product characteristis. [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf"},{"key":"251_CR58","unstructured":"FDA-darolutamide; Nubeqa; Full prescribing information [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf"},{"issue":"4","key":"251_CR59","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JU.0000000000000636","volume":"203","author":"M Marchioni","year":"2020","unstructured":"Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul AK et al (2020) New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol 203(4):751\u2013759","journal-title":"J Urol"},{"issue":"5","key":"251_CR60","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","volume":"50","author":"DC Wedge","year":"2018","unstructured":"Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M et al (2018) Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet 50(5):682\u2013692","journal-title":"Nat Genet"},{"key":"251_CR61","unstructured":"An efficacy and safety study of apalutamide (JNJ-56021927) in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in participants with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02257736"},{"issue":"6_suppl","key":"251_CR62","doi-asserted-by":"crossref","first-page":"TPS383","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS383","volume":"36","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Hussain M, Sternberg CN, Fizazi K, Yamada KS et al (2018) ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 36(6_suppl):TPS383\u2013TPS383","journal-title":"J Clin Oncol"},{"key":"251_CR63","unstructured":"Phase III Radium 223 mCRPC-PEACE III - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02194842"},{"issue":"15_suppl","key":"251_CR64","doi-asserted-by":"crossref","first-page":"TPS5087","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5087","volume":"34","author":"HM Sandler","year":"2016","unstructured":"Sandler HM, McKenzie MR, Tombal BF, Baskin-Bey E, Freedland SJ, Roach M et al (2016) ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy. J Clin Oncol 34(15_suppl):TPS5087","journal-title":"J Clin Oncol"},{"key":"251_CR65","unstructured":"Safety and efficacy study of enzalutamide plus leuprolide in patients with nonmetastatic prostate cancer (EMBARK) - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Aug 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02319837"},{"issue":"16","key":"251_CR66","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s40265-019-01212-y","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Duggan S (2019) Darolutamide: first approval. Drugs. 79(16):1813\u20131818","journal-title":"Drugs."},{"key":"251_CR67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40265-019-1060-5","volume":"79","author":"M Pagliuca","year":"2019","unstructured":"Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G (2019) The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs. Springer International Publishing 79:381\u2013400","journal-title":"Drugs"},{"issue":"25","key":"251_CR68","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","volume":"36","author":"G Attard","year":"2018","unstructured":"Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R et al (2018) Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol 36(25):2639\u20132646","journal-title":"J Clin Oncol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-020-00251-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-020-00251-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-020-00251-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T04:07:20Z","timestamp":1613707640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-020-00251-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1007\/s42000-020-00251-5","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}